GlassScriptPhysician profile
Stephen G Mallette
NPI 1700849411
$8,993.58
in general payments reported to CMS, 2019-2025
29 companies · $1,740 in 2025
The $1,740 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $879 · 2021: $1,399 · 2022: $1,449 · 2023: $1,501 · 2024: $1,405 · 2025: $1,740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,552 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,551.85 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,916.83 | 2019-2025 | |
| Amgen INC. | $1,365.81 | 2019-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $832.96 | 2020-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $791.92 | 2019-2025 | |
| Janssen Biotech, INC. | $714.90 | 2019-2025 | Tremfya, Stelara, Remicade |
| Genzyme Corporation | $698.25 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $632.24 | 2019-2025 | |
| Leo Pharma INC. | $408.90 | 2019-2025 | Adbry |
| Pfizer INC. | $327.05 | 2019-2022 | |
| Lilly USA, LLC | $197.79 | 2019-2025 | Taltz, Ebglyss |
| Genentech USA, INC. | $195.11 | 2020-2025 | Xolair |
| Ucb, INC. | $174.10 | 2019-2025 | Bimzelx |
| Celgene Corporation | $118.99 | 2019 | |
| Galderma Laboratories, L.P. | $105.94 | 2021-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $88.78 | 2022-2025 | Sotyktu |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $81.61 | 2023-2024 | Vtama |
| Paratek Pharmaceuticals, INC. | $57.19 | 2024-2025 | Nuzyra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $44.57 | 2019-2025 | Cabtreo, Siliq, Jublia |
| Organon LLC | $42.93 | 2025 | Vtama |
| Dermira, INC. | $34.10 | 2020 | |
| Vyne Pharmaceuticals INC. | $25.32 | 2020 | |
| Sanofi-Aventis U.S. LLC | $24.93 | 2021 | |
| Mayne Pharma Commercial LLC | $20.36 | 2025 | |
| Arcutis Biotherapeutics, INC. | $19.43 | 2025 | Zoryve |
| Epi Health, LLC | $18.62 | 2022 | |
| Botanix Sb INC | $14.79 | 2025 | Sofdra |
| Incyte Corporation | $14.51 | 2023 | Opzelura |
| Prugen, INC. Pharmaceuticals | $12.92 | 2020 | |
| Taro Pharmaceuticals USA, INC. | $12.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Mallette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.